This is a single
speech (committee meeting) resource
from the openparliament.ca API. If you’re new here, you might want to look at the documentation. If API and JSON are gibberish to you, you’re better off at our main site.
This is a single
speech (committee meeting) resource
from the openparliament.ca API. If you’re new here, you might want to look at the documentation. If API and JSON are gibberish to you, you’re better off at our main site.
{
"time": "2007-04-16 16:05:00",
"attribution": {
"en": "Mr. Sean Thompson (Director, Corporate Development, YM Biosciences Inc., BIOTECanada)",
"fr": ""
},
"content": {
"en": "<p data-HoCid=\"563136\" data-originallang=\"en\">Good afternoon.</p>\n<p data-HoCid=\"563137\" data-originallang=\"en\">YM Biosciences is an early stage cancer product development company, which was founded in 1994. We are currently developing new therapeutic products that we have licensed from the Universities of Saskatchewan, Manitoba, and Dalhousie.</p>\n<p data-HoCid=\"563138\" data-originallang=\"en\">Our most advanced product is nimotuzumab, a biologically derived and produced molecule that is being developed for several underserved cancer indications. The lead indication for nimotuzumab is pediatric pontine glioma, which affects fewer than 50 Canadian children each year. In early studies, nimotuzumab has been shown to improve the quality and length of survival for affected patients.</p>\n<p data-HoCid=\"563139\" data-originallang=\"en\">I'm here today because my company is concerned that CDR, given its history to this point, would reject this Canadian-developed product and deny Canadian patients access to this potentially life-prolonging therapy.</p>\n<p data-HoCid=\"563140\" data-originallang=\"en\">A large part of my job is to identify the financial resources that are necessary to bring exciting new health discoveries to market. Often these development efforts are in partnership with leading multinational pharmaceutical companies or through venture capital investments. That job is made more difficult when venture funds and corporate licensing executives observe that the Canadian marketplace provides little or no market access for innovative biologic products as a direct result of CDR recommendations.</p>\n<p data-HoCid=\"563141\" data-originallang=\"en\">If Canada is to realize the full return on our investments in our universities and programs such as the Canadian Foundation for Innovation, Genome Canada, and the Canadian Institutes of Health Research, we must ensure that the fruits of those investments can reach Canadian patients.</p>\n<p data-HoCid=\"563142\" data-originallang=\"en\">To encourage further investment and development of innovative health inventions, Canada, through the CDR review, must recognize the value of innovation. In the United Kingdom, for example, the National Institute for Health and Clinical Excellence, NICE, a common comparator to CDR, explicitly takes into account the innovative nature of technology and wider societal interests. NICE also works with a citizens council in making reimbursement decisions on new medicines.</p>\n<p data-HoCid=\"563143\" data-originallang=\"en\">Incorporating these elements of the NICE system into CDR would begin to demonstrate that the Canadian system can accommodate the needs of vulnerable patient populations and that it values the innovation of breakthrough therapies.</p>",
"fr": "<p data-HoCid=\"563136\" data-originallang=\"en\">Bonjour. </p>\n<p data-HoCid=\"563137\" data-originallang=\"en\">YM Biosciences est une soci\u00e9t\u00e9 \u00e9mergente qui d\u00e9veloppe des produits de lutte contre le cancer. Elle a \u00e9t\u00e9 fond\u00e9e en 1994. Nous sommes en train de mettre au point de nouveaux produits th\u00e9rapeutiques sous licence des universit\u00e9s de la Saskatchewan, du Manitoba et Dalhousie. </p>\n<p data-HoCid=\"563138\" data-originallang=\"en\">Notre produit principal est le nimotuzumab, une mol\u00e9cule d\u00e9riv\u00e9e produite biologiquement qui est en cours de d\u00e9veloppement pour diverses indications de cancer. La principale indication pour le nimotuzumab est un gliome pontique p\u00e9diatrique qui touche moins de 50 enfants canadiens chaque ann\u00e9e. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le nimotuzumab am\u00e9liore la qualit\u00e9 de vie et la dur\u00e9e de survie des patients touch\u00e9s. </p>\n<p data-HoCid=\"563139\" data-originallang=\"en\">Je suis ici aujourd'hui parce que la soci\u00e9t\u00e9 que je repr\u00e9sente craint que le PCEM, \u00e0 la lumi\u00e8re de ses ant\u00e9c\u00e9dents, rejette ce produit \u00e9labor\u00e9 au Canada et interdise ainsi \u00e0 des patients canadiens l'acc\u00e8s \u00e0 une th\u00e9rapie qui pourrait prolonger leur dur\u00e9e de vie. </p>\n<p data-HoCid=\"563140\" data-originallang=\"en\">Mon travail consiste en grande partie \u00e0 introduire sur le march\u00e9 de nouvelles d\u00e9couvertes fascinantes dans le domaine de la sant\u00e9. Souvent, ces efforts de d\u00e9veloppement se d\u00e9roulent en partenariat avec des multinationales pharmaceutiques ou au moyen d'investissements en coentreprise. Ce travail est rendu encore plus difficile quand les cadres de coentreprises et de grandes soci\u00e9t\u00e9s responsables des licences soulignent que le march\u00e9 canadien offre tr\u00e8s peu d'acc\u00e8s, sinon aucun, aux produits biologiques novateurs, \u00e0 cause des recommandations directes du PCEM.</p>\n<p data-HoCid=\"563141\" data-originallang=\"en\">Pour que le Canada r\u00e9alise le plein potentiel de ses investissements dans les universit\u00e9s et programmes comme la Fondation canadienne pour l'innovation, Genome Canada et les Instituts canadiens de recherche en sant\u00e9, nous devons faire en sorte que le fruit de ces investissements se rende aux patients et patientes du Canada. </p>\n<p data-HoCid=\"563142\" data-originallang=\"en\">Pour encourager les investissements et les inventions novatrices en sant\u00e9, le Canada, par le truchement du PCEM, doit reconna\u00eetre la valeur de l'innovation. Au Royaume-Uni, par exemple, le National Institute for Clinical Excellence, le NICE, qui est comparable au PCEM, tient explicitement compte de la nature novatrice de la technologie et des int\u00e9r\u00eats plus vastes de la soci\u00e9t\u00e9. Le NICE collabore aussi avec un conseil de citoyens : ensemble, ils prennent des d\u00e9cisions concernant le remboursement de nouveaux m\u00e9dicaments. </p>\n<p data-HoCid=\"563143\" data-originallang=\"en\">L'int\u00e9gration des \u00e9l\u00e9ments du NICE au PCEM permettrait de d\u00e9montrer que le syst\u00e8me canadien tient compte des besoins d'une population vuln\u00e9rable et reconna\u00eet la valeur novatrice des th\u00e9rapies de pointe. </p>"
},
"url": "/committees/health/39-1/47/sean-thompson-1/",
"politician_url": null,
"politician_membership_url": null,
"procedural": false,
"source_id": "2002932",
"document_url": "/committees/health/39-1/47/",
"related": {
"document_speeches_url": "/speeches/?document=%2Fcommittees%2Fhealth%2F39-1%2F47%2F"
}
}